# PT-141: research overview > PT-141 (bremelanotide, Vyleesi): research overview — Research Peptide Fundamentals | mybiopeptides — PT-141 in the Research Peptide Fundamentals series on research peptides: one molecule under three names — the research code PT-141, the generic name bremelanotide, and the trademark Vyleesi — and why the choice of name signals regulatory status. **05 — THREE NAMES, ONE MOLECULE** PT-141, bremelanotide and Vyleesi are the same compound. Which name is in use tells a reader which supply chain, and which regulatory status, is under discussion. ## The short version PT-141 is a small ring-shaped peptide, seven amino acids long, that acts on the brain rather than on blood vessels. It switches on **melanocortin receptors** — a receptor family the body uses for several jobs at once, including sexual motivation, appetite, and skin pigmentation. That last item explains a side effect that would otherwise look random: because the same receptor family drives pigment-producing cells, repeated frequent use can darken skin, gums and moles. The naming situation is the sharpest in this hub, because there is no ambiguity about the chemistry and complete ambiguity about the context. **PT-141**, **bremelanotide** and **Vyleesi** name one molecule. But bremelanotide (Vyleesi) is an approved prescription medicine, cleared in June 2019 for one narrowly defined condition in premenopausal women, while material sold as *PT-141 research chemical* sits outside that approval entirely, with no verification of identity, purity or concentration. The molecule is the same. The three names point at completely different realities. ## What it is: the same compound, twice named PT-141 is a synthetic cyclic heptapeptide — a seven-residue ring — and a lactam analogue of alpha-melanocyte-stimulating hormone. Its sequence is written Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge closing the ring between the aspartate and lysine side chains. It is a structural relative of melanotan II, differing in that the C-terminal amide is replaced by a carboxylic acid. Start with the generic name, because it is the most decodable in this hub. **Bremelanotide** ends in the peptide marker **-tide**, exactly as semaglutide and tirzepatide do. But it also carries **melano** in the middle, and that fragment points directly at the melanocortin system the molecule acts on — the same root as in *melanocyte* and in the parent hormone alpha-melanocyte-stimulating hormone. A reader who decodes only that fragment already knows the receptor family, and by extension has a head start on why pigmentation appears among the effects. The research code takes the familiar form: letters, then digits, assigned inside a programme. And in the corpus the compound also appears under fully systematic labels — *cyclo-[Nle4-Asp5]-alpha-MSH(4-10)*, describing the molecule as a modified fragment of the parent hormone, with the parenthetical again specifying a residue range as it did on the **[CJC-1295 page](/cjc-1295)**. Two further variants, *bremelanotide acetate* and *PT-141 acetate*, illustrate one more register: salt-form naming, where the counter-ion is appended because the substance actually handled in a vial is a salt of the free peptide rather than the peptide alone. What makes this compound the pivotal case is that the split between its two main names is not cosmetic. The regulatory record is explicit: bremelanotide was approved in the United States on 21 June 2019 for acquired, generalised hypoactive sexual desire disorder in premenopausal women, and is not approved for men, for postmenopausal women, or to enhance sexual performance. The record then adds the sentence this whole page turns on — that the *PT-141* research-chemical form sits outside that approval. A third register completes the set. The approved product is marketed under the trademark **Vyleesi**, and that name behaves exactly as the trademarks on the **[semaglutide page](/semaglutide)** do: it names a product — a formulation at a specified strength for a specified indication — rather than the molecule. Between them, this compound therefore carries one label from each of the three registers that matter most to a reader: a research code with no regulatory standing, a generic name that identifies the molecule, and a trademark that identifies a marketed product. So the names have quietly become shorthand for different supply chains and different evidence bases, even though no chemist could tell the molecules apart. ## How it works PT-141 activates central melanocortin receptors, chiefly MC4R and to a lesser extent MC3R, which are concentrated in the hypothalamus and limbic system. By stimulating MC4R in hypothalamic circuits such as the medial preoptic area, it is thought to engage dopaminergic pathways governing sexual desire and arousal. The contrast with the more familiar class of treatments is mechanistic and complete. PDE-5 inhibitors act peripherally, on vascular smooth muscle. This compound acts centrally, on the neural circuitry of sexual motivation. It does not work through the hypothalamic-pituitary-gonadal axis, and it does not directly raise testosterone — a common misconception worth correcting explicitly. Neuroimaging supports the central account. In a randomised, double-blind, placebo-controlled crossover fMRI study of 31 premenopausal women with hypoactive sexual desire disorder, MC4R agonism significantly increased sexual desire for up to 24 hours and altered task-based brain processing in response to erotic stimuli, with enhanced amygdala-insula functional connectivity and changes in cerebellar and supplementary-motor activity [23]. The animal literature adds a useful complication rather than a confirmation. In female Syrian hamsters, melanocortin-receptor messenger RNA was concentrated in ventral tegmental area dopamine neurons, but bremelanotide at neither low nor high dose changed melanocortin-receptor expression in the mesolimbic dopamine system, and it did not enhance sexual reward as measured by conditioned place preference — suggesting it does not act on the ventral tegmental to nucleus accumbens reward circuit [22]. A negative finding of that kind narrows the mechanism rather than undermining it: it separates *wanting* from *liking*, and points the effect toward the former. ## What the research shows **The pivotal trials.** Two identical phase 3 randomised controlled trials, together known as RECONNECT and enrolling 1,267 premenopausal women with hypoactive sexual desire disorder, tested bremelanotide 1.75 mg administered subcutaneously as needed. Over 24 weeks both co-primary endpoints were met: sexual desire improved on the integrated FSFI-desire measure by 0.35 (P<0.001), and desire-related distress fell on the integrated FSDS-DAO item by 0.33 (P<0.001), each against placebo. The most common adverse events were nausea, flushing and headache [24]. **Longer-term follow-up.** In the 52-week open-label extension, with 684 women enrolled, no new safety signals emerged and the improvements in sexual desire were sustained. The most common drug-related treatment-emergent adverse events were nausea at 40.4%, flushing at 20.6% and headache at 12.0% [25]. **The regulatory record.** The US prescribing information specifies the approved indication, a 1.75 mg subcutaneous dose taken as needed with a maximum of one dose in 24 hours and no more than eight doses per month, a terminal half-life of about 2.7 hours (range 1.9-4.0), a volume of distribution of 25.0 litres, clearance of 6.5 litres per hour, renal and faecal excretion of 64.8% and 22.8% respectively, and a warning on transient increases in blood pressure, with contraindication in uncontrolled hypertension or cardiovascular disease [26]. Those figures are recorded here as the label's own specification, not as guidance to anyone. **The dissent.** The effect sizes have been challenged. Critical re-analyses argue that the improvements in desire and distress, while statistically significant, are small, and question their clinical meaningfulness and the outcome measures used. Separately, a 2023 Expression of Concern was issued for a 2008 erectile-dysfunction salvage study, whose findings should accordingly be treated as disputed. Both belong in an honest summary. ## Reported effects, cautions and safety This first part is **anecdotal, not clinical evidence** — patient reviews and research-use community accounts, summarised without doses. The most commonly reported benefit is an increase in sexual desire that people describe as starting in the head rather than the body: wanting sex again, feeling mentally switched on in a way they contrast with treatments acting on blood flow. Greater physical arousal and heightened sensitivity are frequently reported, sometimes building without direct stimulation. Easier or more intense orgasm is described as a secondary effect that tends to accompany the rise in desire. In the off-label male research-use community — use that clinicians discussing it describe as off-label — people report spontaneous erections and stronger sexual interest, again characterised as urge-first. A smaller group describe a stronger sense of emotional closeness. Many note a delayed onset, commonly half an hour to a few hours, with a long window of effect that some find convenient and others find hard to plan around. A recurring and honestly reported outcome is no effect at all, sometimes with side effects arriving anyway; responses appear highly individual. Among adverse reports, nausea dominates and is the effect most likely to stop use, typically beginning within about half an hour and lasting a couple of hours, worst with the first dose and easing later. Flushing and warmth across the face, neck and chest are next most common. Headache is frequently reported and usually described as mild and short-lived. Injection-site irritation is common. Tingling or pins-and-needles, restless legs, unusually sensitive skin and brief anxiety cluster with the flushing and nausea soon after a dose. Fatigue or drowsiness for several hours is reported by a number of people. With repeated frequent use, some report darkening of skin, face or gums, new or darker freckles and darkening of existing moles — and some report the darkening did not fully fade after stopping. **Documented cautions.** Approval covers only premenopausal women with the specified condition; use in men, in postmenopausal women, or to boost performance is off-label, and people relying on community reports for those uses are acting outside the studied and labelled population [26][24]. The compound causes a short-lived rise in blood pressure with a matching small fall in heart rate before returning to baseline, which is why the label warns against use by people with uncontrolled hypertension or known cardiovascular disease [26]. Nausea affects a large share of users over long-term use and is a leading reason people stop [25][24]. Skin and mucous-membrane darkening with frequent dosing follows from activation of pigment-related receptors, is more likely in people with darker baseline skin, and may not fully reverse — the labelled limit on dosing frequency exists partly to reduce that risk [26]. Mild rises in liver-related blood markers, and rarely clinically apparent liver injury, have been noted. Material sold as *PT-141 research chemical* sits outside the pharmaceutical approval system, so identity, purity and concentration are unverified, and forensic testing confirms unregulated melanocortin product circulates. Because MC4R also helps control appetite, effects on food intake and body weight are an off-target pharmacological consideration rather than any approved use. And use in pregnancy or breastfeeding is unsupported by controlled human data. ## Where it fits in Research Peptide Fundamentals PT-141 closes the set because it isolates the variable. On the other four pages, differences in naming accompanied differences in chemistry, in receptor family, or in development history. Here the chemistry is held constant and only the name changes — and the consequences remain enormous. Under the name **bremelanotide**, the compound has a regulatory dossier, a specified indication, a labelled dose and dosing ceiling, characterised pharmacokinetics, and a warning list [26]. The approved product reaches the market under a third label again, the trademark **Vyleesi**. Under the name **PT-141**, sold as a research chemical, the same molecule has none of those things attached to it, and its identity and concentration in any given vial are unverified. Nothing about the peptide itself accounts for that difference. It is entirely a fact about which naming system the label was drawn from. This is why the naming register is worth reading first. It is not a matter of etiquette or of using the technically correct term. A generic name signals that a compound completed a process that generates dossiers, labels and monitoring. A research code signals either that the process never completed — as with **[CJC-1295](/cjc-1295)** and **[BPC-157](/bpc-157)** — or, as here, that a supply chain exists in parallel to the approved one and has chosen the older name. One last decodable detail rewards attention. Both **-tide** and **melano** in *bremelanotide* do real work: the first says peptide, the second says melanocortin. A reader who learns to unpack those fragments gets, from the name alone, the class of molecule and the receptor system it acts on. The **[compare page](/compare)** collects that reading key and applies it across all five compounds. --- mybiopeptides reads the peptide literature by its labels — an independent editorial digest of published research, not a clinic, not a pharmacy, and not a source of dosing advice.